Multi-kingdom microbial changes and their associations with the clinical characteristics in schizophrenia patients
Accumulating evidence has highlighted alterations in the gut microbiome in schizophrenia (SZ); however, the role of multi-kingdom microbiota in SZ remains inadequately understood. In this study, we performed metagenomic sequencing of fecal samples from 36 SZ patients and 55 healthy controls (HC) to profile bacterial, fungal, archaeal, and viral communities, along with functional pathways. We also conducted co-occurrence network analysis to explore the relationships among differential microbial species and metabolic pathways separately. Additionally, we assessed the associations of these differential species and functional pathways with clinical characteristics. Our findings revealed significant differences in species between SZ patients and HC, identifying not only 17 bacterial species, but also 8 fungal, 26 archaeal, and 19 viral species. Functional pathway analysis revealed 21 metabolic pathways significantly altered in SZ patients, including an increase in tryptophan metabolism, while biosynthesis of amino acids was decreased. Network analysis further uncovered more complex inter-kingdom interactions in SZ patients, with specific fungal species appearing exclusively in the SZ network. Importantly, significant associations were observed between microbial species and functional pathways with clinical characteristics, including symptom severity, cognitive function, and clinical biochemical marker. For instance, the abundance of Streptococcus vestibularis was positively correlated with homocysteine levels; the ubiquinone and other terpenoid-quinone biosynthesis was positively correlated with both symptom severity and C-reactive protein. Our findings reveal the intricate microbial dysbiosis present in SZ patients, suggesting multi-kingdom microbial interactions play a crucial role in SZ patients, highlighting promising avenues for potential diagnostic and therapeutic applications.
Authors
- Xuetao Shi (ORCID: https://orcid.org/0000-0003-3896-5097)
- Kai Wu (ORCID: https://orcid.org/0000-0003-4467-1597)
- Yuanyuan Huang (ORCID: https://orcid.org/0000-0002-7140-8412)
- Yuping Ning (ORCID: https://orcid.org/0000-0002-5727-2782)
- Hehua Li
- Fengchun Wu (ORCID: https://orcid.org/0000-0003-2817-2341)
- Dongsheng Xiong (ORCID: https://orcid.org/0000-0003-4829-7520)
- Shuhao Chen
- Liqin Liang (ORCID: https://orcid.org/0009-0005-6045-3292)
- Xiaobo Li (ORCID: https://orcid.org/0000-0002-8153-5415)
- Wei Wang (ORCID: https://orcid.org/0000-0001-7788-1895)
- Jing Zhou (ORCID: https://orcid.org/0000-0002-7590-6881)
- Heng Zhang (ORCID: https://orcid.org/0000-0003-3635-5826)
- Junhao Li (ORCID: https://orcid.org/0000-0002-1819-7716)
- Baoyuan Zhu (ORCID: https://orcid.org/0009-0006-6213-214X)
Institutions
- New Jersey Institute of Technology (US)
- First Affiliated Hospital of Guangzhou Medical University (CN)
- Center for Translational Molecular Medicine (NL)
- Guangzhou Psychiatric Hospital (CN)
- Institute of Aging (CA)
- Ministry of Education (MV)
- Guangdong 999 Brain Hospital (CN)
- South China University of Technology (CN)
- Guangzhou Medical University (CN)
Publication Details
- Journal
- Translational Psychiatry
- Published
- 2025-07-05
- DOI
- https://doi.org/10.1038/s41398-025-03449-6
- Citations
- 14
- Primary Topic
- Tryptophan and brain disorders
- Type
- article
- Field-Weighted Citation Impact
- 8.09
Funders
- Guangzhou Medical University
- National Natural Science Foundation of China
- Natural Science Foundation of Guangdong Province
- South China University of Technology
- National Key Research and Development Program of China
- Basic and Applied Basic Research Foundation of Guangdong Province